TEM Tempus AI Stock Outlook 2026: Precision Oncology's AI Data Moat
Tempus AI (TEM) 2026 stock analysis: Q1 revenue $348M (+36%), full-year guidance $1.59B, Merck partnership, path to adjusted EBITDA profitability, and key risks for investors.
TEM Tempus AI HealthcareAI